The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
Gilead Sciences Inc. (NASDAQ: GILD) on Monday shared topline results from the Phase 3 ARTISTRY-2 trial. The trial evaluated the treatment responses of adults with HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results